Toll Free: 1-888-928-9744

Antigen Express, Inc. - Product Pipeline Review - 2014

Published: Oct, 2014 | Pages: 35 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Antigen Express, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Antigen Express, Inc. - Product Pipeline Review - 2014', provides an overview of the Antigen Express, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Antigen Express, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Antigen Express, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Antigen Express, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Antigen Express, Inc.'s pipeline products

Reasons to buy

- Evaluate Antigen Express, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Antigen Express, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Antigen Express, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Antigen Express, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Antigen Express, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Antigen Express, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Antigen Express, Inc. Snapshot 5
Antigen Express, Inc. Overview 5
Key Information 5
Key Facts 5
Antigen Express, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Antigen Express, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Antigen Express, Inc. - Pipeline Products Glance 10
Antigen Express, Inc. - Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
Antigen Express, Inc. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Antigen Express, Inc. - Drug Profiles 13
AE-37 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
AE-08 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
AE-298p 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
AE-443p 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
AEA-35p 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
AEH-10p 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
DNA Vaccine for HIV 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Vaccine for Acute Myelogenous Leukemia 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Vaccine for Allergy 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Antigen Express, Inc. - Pipeline Analysis 24
Antigen Express, Inc. - Pipeline Products by Target 24
Antigen Express, Inc. - Pipeline Products by Route of Administration 25
Antigen Express, Inc. - Pipeline Products by Molecule Type 26
Antigen Express, Inc. - Recent Pipeline Updates 27
Antigen Express, Inc. - Locations And Subsidiaries 33
Head Office 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 35
Disclaimer 35
List of Tables
Antigen Express, Inc., Key Information 5
Antigen Express, Inc., Key Facts 5
Antigen Express, Inc. - Pipeline by Indication, 2014 7
Antigen Express, Inc. - Pipeline by Stage of Development, 2014 8
Antigen Express, Inc. - Monotherapy Products in Pipeline, 2014 9
Antigen Express, Inc. - Phase II, 2014 10
Antigen Express, Inc. - Phase I, 2014 11
Antigen Express, Inc. - Preclinical, 2014 12
Antigen Express, Inc. - Pipeline by Target, 2014 24
Antigen Express, Inc. - Pipeline by Route of Administration, 2014 25
Antigen Express, Inc. - Pipeline by Molecule Type, 2014 26
Antigen Express, Inc. - Recent Pipeline Updates, 2014 27 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify